E

Enzymatica AB (publ)
STO:ENZY

Watchlist Manager
Enzymatica AB (publ)
STO:ENZY
Watchlist
Price: 1.8 SEK 3.45% Market Closed
Market Cap: 436.9m SEK
Have any thoughts about
Enzymatica AB (publ)?
Write Note

Enzymatica AB (publ)
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Enzymatica AB (publ)
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
E
Enzymatica AB (publ)
STO:ENZY
Common Shares Outstanding
kr215.8m
CAGR 3-Years
13%
CAGR 5-Years
9%
CAGR 10-Years
23%
Calliditas Therapeutics AB
STO:CALTX
Common Shares Outstanding
kr54m
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Common Shares Outstanding
kr58.8m
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Common Shares Outstanding
kr158.7m
CAGR 3-Years
10%
CAGR 5-Years
59%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Common Shares Outstanding
kr28m
CAGR 3-Years
62%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Common Shares Outstanding
kr78.1m
CAGR 3-Years
-47%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
No Stocks Found

Enzymatica AB (publ)
Glance View

Market Cap
436.9m SEK
Industry
Pharmaceuticals

Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane and currently employs 26 full-time employees. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.

ENZY Intrinsic Value
1.83 SEK
Undervaluation 2%
Intrinsic Value
Price
E

See Also

What is Enzymatica AB (publ)'s Common Shares Outstanding?
Common Shares Outstanding
215.8m SEK

Based on the financial report for Sep 30, 2024, Enzymatica AB (publ)'s Common Shares Outstanding amounts to 215.8m SEK.

What is Enzymatica AB (publ)'s Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
23%

Over the last year, the Common Shares Outstanding growth was 31%. The average annual Common Shares Outstanding growth rates for Enzymatica AB (publ) have been 13% over the past three years , 9% over the past five years , and 23% over the past ten years .

Back to Top